Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be ...

Wave Life Sciences could offer significant upside if obesity candidate WVE-007 delivers strong human data. Check out the ...

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they ...

Backed by a $2.7 million seed round, the startup is reimagining how intelligent agents can revolutionize high-stakes ...

迈威生物（688062.SH），一家全产业链布局的创新型生物制药公司，与 Calico Life Sciences LLC（以下简称 Calico），一家专注于衰老与年龄相关疾病、由 Alphabet Inc. 和 Arthur D.

SELLAS Life Sciences (SLS) announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board. Dr. Wang is a tenured Associate ...

6月27日，迈威生物（688062）公告称，公司与CALICO LIFE SCIENCES LLC.拟就IL-11靶向治疗（包括9MW3811）签署《独家许可协议》。根据许可协议，迈威生物独家许可CALICO在除大中华区以外的所有区域内独家开发、生产和商业化许可产品的权利。公司可获得首付款及里程碑付款，以及按许可产品净销售额计算的阶梯式特许权使用费。

日前，谷歌旗下抗衰老公司 Calico Life Sciences 宣布与 迈威生物 （Mabwell）达成一项总价近6 亿美元的生物制药交易，以获取针对白介素-11（IL-11）的研究性疗法权益，其中包括一种用于治疗年龄相关疾病的临床阶段单克隆抗体 ...

Investing.com - H.C. Wainwright在atai Life Sciences N.V (NASDAQ: ATAI )的抑郁症治疗药物取得积极的2b期临床试验结果后，重申了对该公司的买入评级和10.00美元的目标价。根据 InvestingPro 数据，分析师目标价格区间为6美元至12美元，目前该股交易价格接近其52周高点2.90美元。

纽约/阿姆斯特丹 - 临床阶段生物制药公司atai Life Sciences (NASDAQ: ATAI )周二宣布已达成协议，将通过普通股和预付费权证进行5000万美元的私募。根据 InvestingPro 数据显示，该公司股价在过去六个月内已上涨超过64%。

With a focus on increasing business investment and growing industries of the future, the UK’s Industrial Strategy released this week sets out its approach to driving long-term growth.

While retrieval augmented generations (RAGs) and agents grab attention, what’s next is really a search across your data.